Benzoic Acid, 4-((4-Amino-3-(4-Cyclohexyl-1-Piperazinyl)-9,10-Dihydro-9,10-Dioxo-1-Anthracenyl)Amino)-
Refractory Malignant Neoplasm
VM Oncology, LLCSmall moleculePhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 33/ 100
- Competitive Position
- 95/ 100
Competitive context
171 Active assets in the Refractory Malignant Neoplasm cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Catequentinib Nanfang Hospital, Southern Medical University | Phase 3 | BB |
Irinotecan M.D. Anderson Cancer Center | Phase 2 | BB |
Durvalumab OHSU Knight Cancer Institute | Phase 2 | BB |
Cediranib National Cancer Institute (NCI) | Phase 2 | BB |
Nivolumab CatalYm GmbH | Phase 2 | BB |
View all 50 →
Same molecule, other indications
Benzoic Acid, 4-((4-Amino-3-(4-Cyclohexyl-1-Piperazinyl)-9,10-Dihydro-9,10-Dioxo-1-Anthracenyl)Amino)- is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →